Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag Phase II in HCV-Related Thrombocytopenia
NCT00110799Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2005
- Primary completion
- Oct 2006
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of eltrombopag in Thrombocytopenia (4 arms), sponsored by GSK. Primary endpoint: Proportion of subjects with a shift from baseline platelet count to >=100,000/µL at 4 weeks. Started Apr 2005; status: completed.
02
Drugs
eltrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT00110799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00110799.